Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05704933 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | completed | Early Phase 1 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03276832 | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02652455 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | completed | Early Phase 1 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04581382 | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03784625 | Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012(MELRIV-1) | completed | Early Phase 1 | 10 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT00962845 | Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | completed | Early Phase 1 | 20 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | completed | Early Phase 1 | 7 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT02320305 | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | completed | Early Phase 1 | 23 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02316795 | Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma | completed | Early Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01789827 | Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy | completed | Early Phase 1 | 5 | Mayo ClinicOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01666353 | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01748747 | Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery | completed | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01568996 | Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions | completed | Early Phase 1 | 17 | John KirkwoodOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00972933 | Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma | completed | Early Phase 1 | 59 | Diwakar DavarOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT01209676 | IMCgp100 in Advanced Unresectable Melanoma | completed | Early Phase 1 | 1 | University of PennsylvaniaOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01425749 | Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI(Mel55) | completed | Early Phase 1 | 25 | Craig L Slingluff, JrOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00276835 | Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer | completed | Early Phase 1 | 15 | Northwestern UniversityOTHER | 1 | Apr 10, 2015 | clinicaltrials |
| NCT00470379 | Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery | completed | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Oct 31, 2014 | clinicaltrials |
| NCT00436410 | Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | completed | Early Phase 1 | 108 | National Institutes of Health Clinical Center (CC)NIH | 1 | May 2, 2012 | clinicaltrials |
| NCT00580060 | Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity | completed | Early Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00743353 | Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5(K5) | completed | Early Phase 1 | 16 | Siemens Molecular ImagingINDUSTRY | 1 | Feb 2, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Apr 6, 2026source: clinicaltrials